JCT  Vol.1 No.4 , December 2010
Expression Compilation of Several Putative Cancer Stem Cell Markers by Primary Ovarian Carcinoma
Abstract: Cancer stem cells (CSCs) or tumor initiating cells are rare cells that are able to establish a tumor or metastasis. Identification of those CSCs is, however, cumbersome even in established cell lines. Several cancer stem cell markers were reported to be expressed by ovarian cancer. Those cancer stem cells are gifted with lower vulnerability to irradiation and cytostatic drugs explaining the high incidence of recurrence after treatment. A variety of different cancer stem cell markers were described for epithelial tumors. Also, cancer cell lines were assessed for stem cell markers with no common denominator. The expression of CD24, CD44, CD117, CD133, ABCG2, ALDH was determined for cells from 22 patients. Ovarian cancer cells were collected from ascites. Part of the tumor cells were analyzed immediately and stained for the above mentioned cancer stem cell markers. The remainder of the cells was cultured for several weeks using standard stem cell culture conditions. We observed a large variety in expression of putative stem cell markers for primary tumors. After two weeks of culture spheres were seen in several cultures, indicative for cancer stem cells, though not all patients’ cells were able to form spheres. Our data show for the first time the heterogeneity in marker display in primary tumors. Also for the cultured cells stem cell markers were determined. None of the stem cell markers was expressed by all patients’ cells. No correlation with tumor type was demonstrated. The complexity of expression challenges the isolation of cancer stem cells
Cite this paper: nullD. Jiabo, Y. Refika, G. Carl, D. Tjitske, M. Leon and T. Ruurd, "Expression Compilation of Several Putative Cancer Stem Cell Markers by Primary Ovarian Carcinoma," Journal of Cancer Therapy, Vol. 1 No. 4, 2010, pp. 165-173. doi: 10.4236/jct.2010.14026.

[1]   R. Gupta, P. Vyas and T. Enver, "Molecular Targeting of Cancer Stem Cells," Cell Stem Cell, Vol. 5, No.2, 2009, pp. 125-6.

[2]   C. Tang, B. T. Ang and S. Pervaiz, "Cancer Stem Cell: Target for Anti-cancer Therapy," Journal of the Federation of American Societies for Experimental Biology, Vol. 21, No.14, 2007, pp. 3777-85.

[3]   M. Al-Hajj, M. W. Becker, M. Wicha, I. Weissman and M. F. Clarke, "Therapeutic Implications of Cancer Stem Cells," Current Opinion in Genetics & Development, Vol. 14, No.1, 2004, pp. 43-7.

[4]   M. Al-Hajj and M. F. Clarke, "Self-renewal and Solid Tumor Stem Cells," Oncogene, Vol. 23, No.43, 2004, pp. 7274-82.

[5]   M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison and M. F. Clarke, "Prospective Identification of Tumorigenic Breast Cancer Cells," Proceedings of the National Academy of Sciences of the United States of America Vol. 100, No.7, 2003, pp. 3983-8.

[6]   G. Dontu, M. Al-Hajj, W. M. Abdallah, M. F. Clarke and M. S. Wicha, "Stem Cells in Normal Breast Development and Breast Cancer," Cell Proliferation, vol. 36 , Suppl.1, 2003, pp. 59-72.

[7]   T. Hussenet, D. Dembele, N. Martinet, J. M. Vignaud and S. du Manoir, "An Adult Tissue-specific Stem Cell Molecular Phenotype is Activated in Epithelial Cancer Stem Cells and Correlated to Patient Outcome," Cell Proliferation, Vol. 9, No.2, 2010, pp. 321-7.

[8]   Bonnet and J. E. Dick, "Human Acute Myeloid Leukemia is Organized as a Hierarchy that Originates from a Primitive Hematopoietic Cell," Nature Medicine, Vol. 3, No.7, 1997, pp. 730-7.

[9]   N. Barker, R. A. Ridgway, J. H. van Es, M. van de Wetering, H. Begthel, M. van den Born, E. Danenberg, A. R. Clarke, O. J. Sansom and H. Clevers, "Crypt Stem Cells as the Cells-of-origin of Intestinal Cancer," Nature, Vol. 457, No.5, 2009, pp. 608-11.

[10]   M. P. Buzzeo, E. W. Scott and C. R. Cogle, "The Hunt for Cancer-initiating Cells: A History Stemming from Leukemia," Leukemia, Vol. 21, No.8, 2007, pp. 1619-27.

[11]   A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower and N. J. Maitland, "Prospective Identification of Tumorigenic Prostate Cancer Stem Cells," Cancer Research, Vol. 65, No.23, 2005, pp. 10946-51.

[12]   P. Dalerba, S. J. Dylla, I. K. Park, R. Liu, X. Wang, R. W. Cho, T. Hoey, A. Gurney, E. H. Huang, D. M. Simeone, A. A. Shelton, G. Parmiani, C. Castelli and M. F. Clarke, "Phenotypic Characterization of Human Colorectal Cancer Stem Cells," Proceedings of the National Academy of Sciences of the USA, Vol. 104, No.23, 2007, pp. 10158-63.

[13]   D. Fang, T. K. Nguyen, K. Leishear, R. Finko, A. N. Kulp, S. Hotz, P. A. Van Belle, X. Xu, D. E. Elder and M. Herlyn, "A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas," Cancer Research, Vol. 65, No.20, 2005, pp. 9328-37.

[14]   P. C. Hermann, S. L. Huber, T. Herrler, A. Aicher, J. W. Ellwart, M. Guba, C. J. Bruns and C. Heeschen, "Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer," Cell Stem Cell, Vol. 1, No.3, 2007, pp. 313-23.

[15]   S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins, J. Squire and P. B. Dirks, "Identification of a Cancer Stem Cell in Human Brain Tumors," Cancer Research, Vol. 63, No.18, 2003, pp. 5821-8.

[16]   S. Zhang, C. Balch, M. W. Chan, H. C. Lai, D. Matei, J. M. Schilder, P. S. Yan, T. H. Huang, and K. P. Nephew, "Identification and Characterization of Ovarian Cancer-initiating Cells from Primary Human Tumors," Cancer Research, Vol. 68, No.11, 2008, pp. 4311-20.

[17]   M. D. Curley, V. A. Therrien, C. L. Cummings, P. A. Sergent, C. R. Koulouris, A. M. Friel, D. J. Roberts, M. V. Seiden, D. T. Scadden, B. R. Rueda and R. Foster, "CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer," Stem Cells, Vol. 27, No.12, 2009, pp. 2875-83.

[18]   G. Ferrandina, E. Martinelli, M. Petrillo, M. G. Prisco, G. Zannoni, S. Sioletic and G. Scambia, "CD133 Antigen Expression in Ovarian Cancer," BioMed Central Cancer, Vol. 9, 2009, pp. 221.

[19]   M. Q. Gao, Y. P. Choi, S. Kang, J. H. Youn and N. H. Cho, "CD24+ Cells from Hierarchically Organized Ovarian Cancer are Enriched in Cancer Stem Cells," Oncogene, Vol. 29, No.18, 2010, pp. 2672-80.

[20]   L. Hu, C. McArthur and R. B. Jaffe, "Ovarian Cancer Stem-like Side-population Cells are Tumourigenic and Chemoresistant," British Journal Of Cancer, Vol. 102, No.8, 2010, pp. 1276-83.

[21]   P. P. Szotek, R. Pieretti-Vanmarcke, P. T. Masiakos, D. M. Dinulescu, D. Connolly, R. Foster, D. Dombkowski, F. Preffer, D. T. Maclaughlin and P. K. Donahoe, "Ovarian Cancer Side Population Defines Cells with Stem Cell-like Characteristics and Mullerian Inhibiting Substance responsiveness," Proceedings of the National Academy of Sciences of the USA, Vol. 103, No.30, 2006, pp. 11154-9.

[22]   L. Patrawala, T. Calhoun, R. Schneider-Broussard, J. Zhou, K. Claypool and D. G. Tang, "Side Population Is Enriched in Tumorigenic, Stem-Like Cancer Cells, whereas ABCG2+ and ABCG2- Cancer Cells are Similarly Tumorigenic," Cancer Research, Vol. 65, No.14, 2005, pp. 6207-6219.

[23]   R. W. Robey, K. K. To, O. Polgar, M. Dohse, P. Fetsch, M. Dean and S. E. Bates, "ABCG2: a Perspective," Advanced Drug Delivery Reviews, Vol. 61, No.11, 2009, pp. 3-13.

[24]   D. Ponti, A. Costa, N. Zaffaroni, G. Pratesi, G. Petrangolini, D. Coradini, S. Pilotti, M. A. Pierotti and M. G. Daidone, "Isolation and in Vitro Propagation of Tumorigenic Breast Cancer Cells with Stem/progenitor Cell Properties," Cancer Research, Vol. 65, No.13, 2005, pp. 5506-11.

[25]   S. A. Bapat, A. M. Mali, C. B. Koppikar, and N. K. Kurrey, "Stem and Progenitor-Like Cells Contribute to the Aggressive Behavior of Human Epithelial Ovarian Cancer," Cancer Research, Vol. 65, No.8, 2005, pp. 3025-3029.

[26]   T. Liu, W. Cheng, D. Lai, Y. Huang and L. Guo, "Characterization of Primary Ovarian Cancer Cells in Different Culture Systems," Oncology Reports, Vol. 23, No.5, 2010, pp. 1277-84.

[27]   M. Y. Fong and S. S. Kakar, "The Role of Cancer Stem Cells and the Side Population in Epithelial Ovarian Cancer," Histology and Histopathology, Vol. 25, No.1, 2010, pp. 113-20.

[28]   S. Deng, X. Yang, H. Lassus, S. Liang, S. Kaur, Q. Ye, C. Li, L. P. Wang, K. F. Roby, S. Orsulic, D. C. Connolly, Y. Zhang, K. Montone, R. Butzow, G. Coukos and L. Zhang, "Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers," Public Library of Science ONE, Vol. 5, No.4, pp. e10277.

[29]   B. Chang, G. Liu, F. Xue, D. G. Rosen, L. Xiao, X. Wang and J. Liu, "ALDH1 Expression Correlates with Favorable Prognosis in Ovarian Cancers," Modern Pathology, Vol. 22, No.6, 2009, pp. 817-23.

[30]   S. Y. Park, H. E. Lee, H. Li, M. Shipitsin, R. Gelman and K. Polyak, "Heterogeneity for Stem Cell Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer," Clinical Cancer Research, Vol. 16, No.3, 2010, pp. 876-887.

[31]   C. H. Stuelten, S. D. Mertins, J. I. Busch, M. Gowens, D. A. Scudiero, M. W. Burkett, K. M. Hite, M. Alley, M. Hollingshead, R. H. Shoemaker and J. E. Niederhuber, "Complex Display of Putative Tumor Stem Cell Markers in the NCI60 Tumor Cell Line Panel," Stem Cells, Vol. 28, No.4, 2010, pp. 649-660.

[32]   E. Katz, K. Skorecki and M. Tzukerman, "Niche-dependent Tumorigenic Capacity of Malignant Ovarian Ascites-derived Cancer Cell Subpopulations," Clinical Cancer Research, Vol. 15, No.1, 2009, pp. 70-80.

[33]   M. K?bel, S. E. Kalloger, N. Boyd, S. McKinney, E. Mehl, C. Palmer, S. Leung, N. J. Bowen, D. N. Ionescu, A. Rajput, L. M. Prentice, D. Miller, J. Santos, K. Swenerton, C. B. Gilks and D. Huntsman, "Ovarian Carcinoma Subtypes are Different Diseases: Implications for Biomarker Studies," Public Library of Science Medicine, Vol. 5, 2008, pp. e232.